Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about ASCENDIS PHARMA A/S
01/13Wedbush Raises Price Target for Ascendis Pharma A/S to $189 From $186 on EU Approval fo..
MT
01/13Ascendis Pharma's Growth Hormone Drug TransCon hGH Gets EU Approval
MT
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gr..
AQ
01/13Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Gro..
CI
01/13Wedbush Cuts Ascendis Pharma's PT to $186 From $191 on Skytrofa Contraindication for PW..
MT
01/11European ADRs Nudge Lower in Tuesday Trading
MT
01/10Ascendis Pharma A/S Provides Update on Vision 3x3 Strategic Roadmap at 40th Annual J.P...
AQ
01/06European ADRs Move Higher in Thursday Trading
MT
01/06Cowen Starts Ascendis Pharma at Market Perform With $136 Price Target
MT
01/05European ADRs Move Higher in Wednesday Trading
MT
01/04Ascendis Pharma A/S to Participate in 40th Annual J.P. Morgan Healthcare Conference
GL
2021Ascendis Pharma A/S Virtual R&D Program Update Highlights Continued Development Across ..
AQ
2021Ascendis Pharma A/S to Provide an Update on Two of Its Investigational Endocrinology Ra..
CI
2021Wells Fargo Starts Ascendis Pharma at Overweight With $176 Price Target
MT
2021Ascendis Pharma A/S to Host Virtual R&D Program Update on December 14
GL
2021European ADRs Move Sharply Lower in Friday Trading
MT
2021Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forwar..
GL
2021Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward..
CI
2021Ascendis Pharma A/S Elects Rafa?le Tordjman as A Class II Director
CI
2021Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
AQ
2021European ADRs Mixed in Tuesday Morning Trading
MT
2021SVB Leerink Adjusts Ascendis Pharma's Price Target to $190 from $182, Keeps Outperform ..
MT
2021Ascendis Pharma A/S - Share Repurchase Program Update
AQ
2021Ascendis Pharma Says EMA Panel Issues Positive Opinion Backing Approval of Growth Hormo..
MT
2021Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients..
GL
2021Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon? hGH for Patients with ..
CI
2021Credit Suisse Lowers Ascendis Pharma's PT to $179 from $185, Updates Model with Q3 Actu..
MT
2021Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results - Form 6-K
PU
2021ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEME..
PU
2021Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
2021Ascendis Pharma's Q3 Loss Shrinks Even as Revenue Slips
MT
2021Tranche Update on Ascendis Pharma A/S's Equity Buyback Plan announced on September 29, ..
CI
2021Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results
AQ
2021Ascendis Pharma A/S's Equity Buyback announced on September 29, 2021, has expired with ..
CI
2021Ascendis Pharma A/S Presents New Non-Clinical Dataáfor TransCon™ TLR7/8 Agonist O..
AQ
2021Ascendis Pharma A/S Presents New Non-Clinical Data?for TransCon TLR7/8 Agonist Oncology..
CI
2021Ascendis Pharma A/S - Share Repurchase Program Update
AQ
2021Ascendis Pharma A/S Announces Third Quarter 2021 Financial Resultsáand Business Update ..
AQ
2021Trump's real-estate empire pays the price for poisonous politics
RE
2021ASCENDIS PHARMA A/S : Notice to convene Extraordinary General Meeting - Form 6-K
PU
2021ASCENDIS PHARMA A/S : BofA Securities Downgrades Ascendis Pharma to Neutral From Buy, Lift..
MT
2021ASCENDIS PHARMA A/S : Wedbush Lifts Price Target for Ascendis Pharma A/S to $191 From $187..
MT
2021Certain Ordinary Shares of Ascendis Pharma A/S are subject to a Lock-Up Agreement Endin..
CI
2021Certain Warrants of Ascendis Pharma A/S are subject to a Lock-Up Agreement Ending on 1..
CI
2021U.S. Supreme Court refuses stay request for Spire Missouri natgas pipe
RE
2021Health Care Stocks Climb Pre-Bell Friday
MT
2021ASCENDIS PHARMA A/S : Health Care
MT
2021ASCENDIS PHARMA A/S : INCORPORATION BY REFERENCE - Form 6-K
PU
2021ASCENDIS PHARMA A/S : Begins US Commercial Launch of Pediatric Growth Hormone Deficiency T..
MT
2021ASCENDIS PHARMA A/S : Announces U.S. Commercial Launch of SKYTROFA« (Lonapegsomatropin-tcg..
AQ
2021Ascendis Pharma A/S Announces U.S. Commercial Launch of Skytrofa the First and Only FDA..
CI
2021European ADRs Move Lower in Wednesday Trading
MT
2021ASCENDIS PHARMA A/S : Articles of Association (Form 6-K)
PU
2021ASCENDIS PHARMA A/S : A/S Announces Presentations for TransCon™áPTH and TransCon&tra..
GL
2021Ascendis Pharma A/S Announces Presentations for TransCon PTH and TransCon CNP at the Am..
CI
2021ASCENDIS PHARMA A/S : to Buy Back Up to $25 Million in American Depositary Shares by Year-..
MT
2021ASCENDIS PHARMA A/S : Announces Share Repurchase Program
AQ
2021Ascendis Pharma A/S announces an Equity Buyback for 300,000 shares, for $25 million.
CI
2021Ascendis Pharma A/S authorizes a Buyback Plan.
CI
2021PRIME MINING : Appoints New Board Member and Exploration Executive, Provides Update
MT
2021European ADRs Move Sharply Higher in Thursday Trading
MT
2021ASCENDIS PHARMA A/S : INCORPORATION BY REFERENCE (Form 6-K)
PU
2021Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Fo..
GL
2021Ascendis Pharma A/S Announces Mean Bone Mineral Density Data from Phase 2 PaTH Forward ..
CI
2021ASCENDIS PHARMA A/S : Articles of Association (Form 6-K)
PU
2021ASCENDIS PHARMA A/S : Seeks FDA Nod to Start TransCon Trial in Patients with Advanced Canc..
MT
2021Ascendis Pharma A/S Announces Upcoming Investor Presentations
GL
2021Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon&t..
GL
2021Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransConÖ ..
CI
2021European ADRs Move Lower in Tuesday Trading
MT
2021European ADRs Move Higher in Thursday Trading
MT
2021ASCENDIS PHARMA A/S : Prices Offering at $160 Per ADS
MT
2021Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
GL
2021Health Care Stocks Reverse Losses as Biotechs Rise
MT
2021ADRs End Mostly Higher, Ascendis Pharma Trades Actively
DJ
1  2  3  4  5  6  7Next
Upcoming event on ASCENDIS PHARMA A/S